FutureSenseIndia

Suraksha Diagnostic IPO 2024: Detailed Insights, Dates, and Analysis

Suraksha Diagnostic IPO 2024

Suraksha Diagnostic IPO: A Comprehensive Overview

The Suraksha Diagnostic Initial Public Offering (IPO) offers an intriguing investment opportunity in the healthcare sector. The IPO will open on November 29, 2024, and close on December 3, 2024. Below are the essential details:


IPO Highlights

Objective

  • Suraksha Diagnostic aims to raise ₹846.25 crores through a mix of:
    • Fresh issue of shares (amount unspecified).
    • Offer for sale of 1,91,89,330 equity shares by existing shareholders.

Key Dates

  • Opening/Closing: November 29 – December 3, 2024
  • Allotment Finalization: December 4, 2024
  • Refunds and Demat Credit: December 5, 2024
  • Listing Date: December 6, 2024, on BSE and NSE

Price Band & Lot Size

  • Price Band: ₹420 – ₹441 per share
  • Minimum Lot Size: 34 shares (~₹14,994)
  • Maximum for Retail Investors: 13 lots (442 shares, ~₹1,94,922)

Investor Quotas

  • Retail Investors: 35%
  • Qualified Institutional Buyers (QIB): 50%
  • Non-Institutional Investors (NII): 15%

Registrar & Lead Managers

  • Registrar: KFin Technologies Limited
  • Lead Manager: Nuvama Wealth and Investment Limited

Financial Overview

Suraksha Diagnostic has demonstrated consistent growth and profitability:

Financial Summary (₹ in Crores)

Year Revenue Expense Profit After Tax (PAT) Total Assets
2022 ₹223.19 ₹197.76 ₹20.82 ₹275.96
2023 ₹190.13 ₹186.94 ₹6.07 ₹281.20
2024 ₹218.71 ₹190.03 ₹23.13 ₹300.21

Key Performance Indicators (KPIs)

  • Return on Equity (ROE): 14.09%
  • Return on Capital Employed (ROCE): 21.46%
  • EBITDA Margin: 33.66%
  • PAT Margin: 10.57%
  • Debt-to-Equity Ratio: 0.20
  • Earnings Per Share (EPS): ₹4.43 (Basic)
  • Net Asset Value (NAV): ₹33.66

Investment Highlights

  1. Market Presence: Suraksha Diagnostic is a dominant player in Eastern India, with a growing network of diagnostic centers.
  2. Robust Financial Performance: Strong profitability with a 20.87% revenue CAGR from FY2022 to FY2024.
  3. Expanding Service Offerings: Over 2,300 tests in pathology, radiology, and advanced diagnostics.
  4. Experienced Workforce: The company employs 1,522 permanent staff, showcasing its operational strength.

Promoters

  • Dr. Somnath Chatterjee
  • Ms. Ritu Mittal
  • Mr. Satish Kumar Verma

The Suraksha Diagnostic IPO highlights the potential for growth in India’s healthcare and diagnostics sector. While the company shows promise with a strong market presence and positive financial performance, investors should weigh risks, review the prospectus, and consult financial advisors for informed decision-making.

Leave a Reply

Your email address will not be published. Required fields are marked *